About Eurogentec
Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
Eurogentec was founded in 1985. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets.
The life science BU specializes in Genomics (e.g. Lab scale to Large scale Oligonucleotides, PCR/qPCR Kits & Reagents and Assay Dispensing Service) and Proteomics (e.g. catalog and custom peptides & antibodies including a 28-Day Speedy protocol, assay kits and Proprietary Dyes & Quenchers).
The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications.
The Biomanufacturing BU is a GMP Biomanufacturer specialized in the technology transfer, process development, scale-up and manufacturing of proteins, plasmids and vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements.
- Focus : Service
- Industry : Biotechnology, Laboratory equipment / supplies
Product portfolio of Eurogentec
Here you will find Eurogentec S.A.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous